Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Repurchased
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Integra Lifesciences Holdings (IART) Change in Inventory (2016 - 2025)

Integra Lifesciences Holdings (IART) has disclosed Change in Inventory for 17 consecutive years, with $3.3 million as the latest value for Q4 2025.

  • Quarterly Change in Inventory rose 486.14% to $3.3 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $46.8 million through Dec 2025, up 66.12% year-over-year, with the annual reading at $46.8 million for FY2025, 66.12% up from the prior year.
  • Change in Inventory hit $3.3 million in Q4 2025 for Integra Lifesciences Holdings, down from $23.3 million in the prior quarter.
  • In the past five years, Change in Inventory ranged from a high of $25.4 million in Q1 2023 to a low of -$9.0 million in Q4 2021.
  • Historically, Change in Inventory has averaged $7.9 million across 5 years, with a median of $6.4 million in 2021.
  • Biggest YoY gain for Change in Inventory was 529.87% in 2021; the steepest drop was 418.49% in 2021.
  • Year by year, Change in Inventory stood at -$9.0 million in 2021, then skyrocketed by 152.17% to $4.7 million in 2022, then surged by 250.84% to $16.4 million in 2023, then tumbled by 96.53% to $570000.0 in 2024, then soared by 486.14% to $3.3 million in 2025.
  • Business Quant data shows Change in Inventory for IART at $3.3 million in Q4 2025, $23.3 million in Q3 2025, and $6.4 million in Q2 2025.